Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference

Presentation will Cover Recent Corporate Milestones Including Acceleration of Manufacturing Readiness for Entolimod™

FREMONT, CA / ACCESS Newswire / January 20, 2026 / Tivic Health Systems, Inc. (NASDAQ:TIVC), a late-stage immunotherapeutics company, today announced that its CEO will provide a corporate update focused on recent developments in its advancement of Entolimod during the Emerging Growth Virtual Conference on January 21 and 22, 2026

WHO: Jennifer Ernst, Chief Executive Officer
WHERE: January 22, 2026
WHEN: 4:10 - 4:20 Eastern Time

During the virtual conference update, Ms. Ernst will highlight recent company developments, including scale-up validation for Entolimod manufacturing and the vertical integration of Velocity Bioworks-a San Antonio-based contract development and manufacturing organization which provides the company with in-house manufacturing capability and new potential revenue streams. This strategic addition is expected to reduce production costs, eliminate outsourcing delays, and accelerate validation of current Good Manufacturing Practice (cGMP) for Entolimod, demonstrated in recent scale-up.

Attendees are encouraged to attend and/or listen to the presentation. Please register for the event at the below link.

https://goto.webcasts.com/starthere.jsp?ei=1717095&tp_key=3c898db1bd&s ...

If attendees cannot join the event live on the day of the conference, an archived webcast will also be made available on www.EmergingGrowth.com.

About the Emerging Growth
The Emerging Growth Virtual Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Entolimod
Entolimod is a novel Toll-like Receptor 5 (TLR5) agonist that triggers NF-kappaB pathway signaling, activating anti-apoptotic and cell protective mechanisms. Entolimod for Acute Radiation Syndrome (ARS) has been the subject of extensive trials under the FDA's Animal Rule and in animal models has demonstrated robust survival rates, enhanced gastrointestinal tract recovery, and improved hematopoiesis. To see the complete Tivic pipeline visit: https://tivichealth.com/pipeline/